Your browser doesn't support javascript.
loading
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.
Brown, Christopher R; Gupta, Swati; Qin, June; Racie, Timothy; He, Guo; Lentini, Scott; Malone, Ryan; Yu, Mikyung; Matsuda, Shigeo; Shulga-Morskaya, Svetlana; Nair, Anil V; Theile, Christopher S; Schmidt, Karyn; Shahraz, Azar; Goel, Varun; Parmar, Rubina G; Zlatev, Ivan; Schlegel, Mark K; Nair, Jayaprakash K; Jayaraman, Muthusamy; Manoharan, Muthiah; Brown, Dennis; Maier, Martin A; Jadhav, Vasant.
Afiliação
  • Brown CR; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Gupta S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Qin J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Racie T; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • He G; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Lentini S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Malone R; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Yu M; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Matsuda S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Shulga-Morskaya S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Nair AV; MGH Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Theile CS; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Schmidt K; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Shahraz A; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Goel V; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Parmar RG; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Zlatev I; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Schlegel MK; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Nair JK; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Jayaraman M; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Manoharan M; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Brown D; MGH Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Maier MA; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
  • Jadhav V; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
Nucleic Acids Res ; 48(21): 11827-11844, 2020 12 02.
Article em En | MEDLINE | ID: mdl-32808038
ABSTRACT
One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclinical species and humans. Here, we investigated the underlying biology supporting this extended duration of pharmacological activity. We found that siRNA accumulation and stability in acidic intracellular compartments is critical for long-term activity. We show that functional siRNA can be liberated from these compartments and loaded into newly generated Argonaute 2 protein complexes weeks after dosing, enabling continuous RNAi activity over time. Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose-adjusted to achieve similar knockdown, but only GalNAc-siRNAs supported an extended duration of activity, illustrating the importance of receptor-mediated siRNA trafficking in the process. Taken together, we provide several lines of evidence that acidic intracellular compartments serve as a long-term depot for GalNAc-siRNA conjugates and are the major contributor to the extended duration of activity observed in vivo.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetilgalactosamina / Pré-Albumina / Portadores de Fármacos / Inativação Gênica / Receptor de Asialoglicoproteína / RNA Interferente Pequeno Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetilgalactosamina / Pré-Albumina / Portadores de Fármacos / Inativação Gênica / Receptor de Asialoglicoproteína / RNA Interferente Pequeno Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article